December 9, 2024 – As part of the company´s ongoing efforts to increase our visibility in Italy and strengthen relationships with the Italian community, Oncopeptides recently launched www.oncopeptides.it.
December 4, 2024 – Oncopeptides CEO Sofia Heigis recently participated at Redeye´s Technology and Life Science event in Stockholm.
December 9, 2024
As part of the company´s ongoing efforts to increase our visibility in Italy and strengthen relationships with the Italian community, Oncopeptides recently launched www.oncopeptides.it
Read more
December 4, 2024
In this edition of Oncopeptalks, David meets with the fast growing Italian Oncopeptides team to discuss their journey to the approval in Italy and their priorities ahead of the launch planned for early next year.
Read more
November 27, 2024
In this episode of Oncopeptalks, David and Sofia cover the recent announcement that Oncopeptides obtains reimbursement for Pepaxti in Italy.
Read moreNovember 20, 2024
Oncopeptides today announces that an evaluation of the activity of two peptide drug conjugates (PDCs) developed by Oncopeptides in relapsed or refractory Acute Myeloid Leukemia has been accepted as a poster and will be presented at the 66th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego, California between December 7-10.
Read moreJuly 22, 2024
Oncopeptides recently announced entry of the first patient in a new study evaluating the real-world effectiveness and safety of Pepaxti in German patients.
Read moreJune 27, 2024
Oncopeptides recently announced that the first candidate drug based on the company´s unique platform for Small Polypeptide based innate Killer Engagers (SPiKE) has been selected.
Read more
December 4, 2024
Oncopeptides CEO Sofia Heigis recently participated at Redeye´s Technology and Life Science event in Stockholm.
Read more
November 28, 2024
Oncopeptides' CEO Sofia Heigis presented the company at Stora Aktiedagarna organized by the organization Aktiespararna.
Read more
November 22, 2024
You can watch the presentation and the following Q&A.
Read more
Released November 7, 2024
CEO Sofia Heigis
David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68
Oncopeptides AB Year-end report 2024 will be published February 27, 2025
Press release - November 27, 2024
2025-01-28 - 2025-02-26
Other
2025-02-27
Report
2025-04-08 - 2025-05-07
Other
”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”
We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.
Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden’s leading cancer researchers and cancer research institutions.